RGNX - REGENXBIO Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
64,242
218,505
10,393
4,589
7,588
Cost of Revenue
7,293
9,640
1,709
959
1,503
Gross Profit
56,949
208,865
8,684
3,630
6,085
Operating Expenses
Research Development
114,707
83,873
57,224
45,482
17,279
Selling General and Administrative
48,509
36,850
27,229
23,590
11,912
Total Operating Expenses
163,173
120,765
84,569
68,970
29,165
Operating Income or Loss
-106,224
88,100
-75,885
-65,340
-23,080
Interest Expense
-
-
0
0
20
Total Other Income/Expenses Net
40,843
7,070
2,716
1,938
289
Income Before Tax
-62,706
104,116
-73,169
-63,402
-22,811
Income Tax Expense
1,257
4,179
0
-435
-
Income from Continuing Operations
-63,963
99,937
-73,169
-62,967
-22,811
Net Income
-63,963
99,937
-73,169
-62,967
-22,811
Net Income available to common shareholders
-63,963
99,937
-73,169
-62,967
-23,799
Reported EPS
Basic
-
2.99
-2.45
-2.38
-2.59
Diluted
-
2.73
-2.45
-2.38
-2.59
Weighted average shares outstanding
Basic
-
33,427
29,878
26,409
9,173
Diluted
-
36,648
29,878
26,409
9,173
EBITDA
-
92,082
-73,199
-62,858
-22,711